Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Summary

Postprandial hyperinsulinemic hypoglycemia is a well-known and potentially severe complication of Roux-en-Y gastric bypass (RYGB), and the treatment options are limited. Pasireotide has shown to be effective in preventing hypoglycemia in RYGB operated subjects, however treatment often leads to increased hyperglycemia. The purpose of this study is to investigate two doses of pasireotide that are lower than doses previously used in RYGB operated subjects with postprandial hyperinsulinemic hypoglycemia.

Timeline

Start

2018-06-01

Primary completion

2018-08-01

Completion

2018-11-01

Drugs

Indications